Effect of LY2062430 an Anti-Amyloid Beta Monoclonal Antibody on the Progression of Alzheimer
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The primary objective of this study is to test whether solanezumab will slow the rate of mental (thinking and remembering) decline of Alzheimer
Description
The primary objective of this study is to test whether solanezumab will slow the rate of mental (thinking and remembering) decline of Alzheimer
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer
-
Age: Between 55 Years - 100 Years
-
Gender: All
Updated on
24 Apr 2024.
Study ID: 1010002694 (0906-02)
